Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations

Por Kersten, M J, Kraan, W, Doorduijn, J, Bromberg, J, Lam, K, Kluin, P M, van der Holt, B J, Spaargaren, M, Pals, S T
Publicado no Blood Cancer J (2014)

OS4.2 Radiological response assessment in the era of bevacizumab: RANO or volumetry? A report from the BELOB trial.

Por Gahrmann, R., van den Bent, M., van der Holt, B., Vernhout, R., Taal, W., Taphoorn, M., de Groot, J., Beerepoot, L., Jasperse, B., Smits, M.
Publicado no Neuro Oncol (2016)

P04.24 Apparent diffusion coefficient histogram analysis in recurrent glioblastoma predicts overall survival after the first course of bevacizumab and lomustine

Por Gahrmann, R., Leemans, A., van der Holt, B., Vernhout, R. M., Taal, W., Vos, M., de Groot, J. C., Hanse, M., van den Bent, M., Smits, M.
Publicado no Neuro Oncol (2017)

Heterogeneity in the in vitro survival and proliferation of human seminoma cells.

Por Olie, R. A., Looijenga, L. H., Dekker, M. C., de Jong, F. H., van Dissel-Emiliani, F. M., de Rooij, D. G., van der Holt, B., Oosterhuis, J. W.
Publicado em 1995

In vivo fluorescence kinetics and localisation of aluminum phthalocyanine disulphonate in an autologous tumour model.

Por Witjes, M. J., Speelman, O. C., Nikkels, P. G., Nooren, C. A., Nauta, J. M., van der Holt, B., van Leengoed, H. L., Star, W. M., Roodenburg, J. L.
Publicado em 1996

IDENTIFICATION OF PATIENTS WITH RECURRENT GBM THAT BENEFIT FROM BEVACIZUMAB

Por French, Pim, Erdem-Eraslan, L., Kros, J.M., Oosterkamp, H.M., Walenkamp, A.M.E., Beerepoot, L., Hanse, M., Buter, J., Honkoop, A., van der Holt, B., Vernhout, R.M., Sillevis Smitt, P.A.E., Taal, W., van den Bent, M.J.
Publicado em 2014

Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomusti...

Por Beije, N, Kraan, J, Taal, W, van der Holt, B, Oosterkamp, H M, Walenkamp, A M, Beerepoot, L, Hanse, M, van Linde, M E, Otten, A, Vernhout, R M, de Vos, F Y F, Gratama, J W, Sleijfer, S, van den Bent, M J
Publicado no Br J Cancer (2015)

O10.05 FINAL ANALYSIS OF THE BELOB TRIAL (A RANDOMIZED PHASE II STUDY ON BEVACIZUMAB VERSUS BEVACIZUMAB PLUS LOMUSTINE VERSUS LOMUSTINE SINGLE AGENT IN RECURRENT GLIOBLASTOMA) AND...

Por Taal, W., Oosterkamp, H.M., Walenkamp, A.M.E., Dubbink, H.J., Beerepoot, L.V., Hanse, M., Buter, J., Honkoop, A., Boerman, D., Vos, F.Y.F., Dinjens, W.N.M., Enting, R.H., Taphoorn, M.J.B., van den Berkmortel, F.W.P.J., Jansen, R., Brandsma, D., Bromberg, J.E., van Heuvel, I., Vernhout, R.M., van der Holt, B., van den Bent, M.J.
Publicado em 2014